Alnylam Pharmaceuticals
Cambridge
Massachusetts
United States
1308 articles about Alnylam Pharmaceuticals
-
Alnylam Pharmaceuticals to Webcast Presentations at Upcoming Investor Conferences
2/13/2012
-
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
2/10/2012
-
Alnylam Pharmaceuticals Scientists Discover Novel Method for Monitoring RNAi Activity in Blood Samples
2/9/2012
-
Alnylam Pharmaceuticals to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial Results
2/3/2012
-
Alnylam Pharmaceuticals Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Second Generation Lipid Nanoparticles (LNP) for Systemic Delivery of RNAi Therapeutics
1/30/2012
-
Alnylam Pharmaceuticals to Shed a Third of Its Work Force
1/23/2012
-
Alnylam Pharmaceuticals Files Patent Infringement Suit Against Tekmira Pharmaceuticals Corporation
1/17/2012
-
Alnylam Pharmaceuticals Provides Key 2012 Goals for RNAi Therapeutics Pipeline
1/9/2012
-
Alnylam Pharmaceuticals Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis
1/6/2012
-
Alnylam Pharmaceuticals to Webcast Presentation at 30th Annual J.P. Morgan Healthcare Conference 2012
1/5/2012
-
Alnylam Pharmaceuticals and Arrowhead Research Corporation Form Collaboration and Licensing Agreement
1/5/2012
-
Alnylam Pharmaceuticals Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia
1/4/2012
-
Alnylam Pharmaceuticals Announces Publication of Pre-clinical Results with ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington’s Disease, in Experimental Neurology
12/28/2011
-
Alnylam Pharmaceuticals Scientists Present New Data on RNAi Therapeutics at 53rd American Society of Hematology Annual Meeting
12/13/2011
-
Alnylam Pharmaceuticals Completes Enrollment in Phase IIb Study of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
11/29/2011
-
Alnylam Pharmaceuticals to Webcast Presentation at the Piper Jaffray 23rd Annual Health Care Conference
11/23/2011
-
Alnylam Pharmaceuticals Presents Positive Preliminary Clinical Results for ALN-TTR01, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
11/21/2011
-
Alnylam Pharmaceuticals Grants InterfeRx™ Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics
11/17/2011
-
Alnylam Pharmaceuticals to Present Phase I Clinical Data at VIIIth International Symposium on Familial Amyloidotic Polyneuropathy
11/15/2011
-
Alnylam Pharmaceuticals Reports Third Quarter 2011 Financial Results
11/2/2011